表紙
市場調查報告書

Aminoglycosides的全球市場:成長率,趨勢及預測分析(2019年∼2024年)

Aminoglycosides Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 866599
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
Back to Top
Aminoglycosides的全球市場:成長率,趨勢及預測分析(2019年∼2024年) Aminoglycosides Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年05月01日內容資訊: 英文 112 Pages
簡介

全球Aminoglycosides市場,由於導致抗生素的高利用的動物疾病的發生增加的負擔,預測期間預測將以4.3%以上的年複合成長率成長。

本報告提供全球Aminoglycosides市場相關調查分析,市場概要,市場動態,市場區隔,各地區的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 病的治療不能狀態
    • 高齡化人口全世界性增加
    • 腦功能障礙的罹患率增加
  • 市場阻礙因素
    • Aminoglycosides相關的有害及中毒反應
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭激烈度

第5章 市場區隔

  • 產品
    • 新霉素
    • Tobramycin
    • 慶大霉素
    • Amikacin
    • Paromomycin
    • 鏈黴素
    • 卡那霉素
    • 其他Aminoglycosides
  • 給藥途徑
    • 非口服
    • 乳腺內
    • 局部
    • 口服
  • 應用
    • 獸醫
    • 皮膚感染疾病
    • 呼吸疾病
    • 泌尿道感染(UTI)和骨盆疾病
    • 其他病
  • 地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Alfasan International BV
    • Hangzhou Uniwise International Co., Ltd.
    • HuvePharma
    • Jiangxi Bolai Pharmacy Co., Ltd.
    • Kremoint Pharma Pvt. Ltd
    • Medico Remedies Pvt. Ltd
    • Medson Pharmaceuticals
    • Vega Pharma Ltd.
    • Xian Wison Biological Technology Co., Ltd.
    • Yi Chang Veterinary Medicine Factory

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 66092

Market Overview

The global aminoglycosides market size is expected to witness a growth of over 4.3% CAGR over the forecast period, owing to the increasing burden of animal disease outbreaks leading to high utilization of antibiotics.

Moreover, this class of antibiotics is found to be effective even when bacterial inoculum is large, and are frequently used as a second line of defense against basic infection resistant to basic antibacterials. Additionally, reduction in the prescription rate of aminoglycoside antibiotics due to side effects associated with the usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade is expected to affect the market growth negatively.

Scope of the Report

As per the scope of the report, aminoglycosides are highly potent, antibiotics with several properties for the treatment of life-threatening infections. Aminoglycosides have concentration-dependent bactericidal activity by binding to the 30S ribosome that inhibits bacterial protein synthesis.

Key Market Trends

Gentamicin Accounted for the Largest Share in the Global Market

Neomycin, streptomycin, gentamicin, kanamycin, tobramycin, amikacin, and others are included in the product categorization of aminoglycosides. Streptomycin is a first level antibacterial used for the treatment of tuberculosis. Aminoglycosides used in the treatment of MDR-TB include kanamycin capreomycin and amikacin.

Gentamicin is the agent of choice for major bacterial infections amongst others. Tobramycin has been found to be slightly more effective against Pseudomonas aeruginosa infections. Amikacin and gentamicin find maximum usage in veterinary medicine. Gentamicin is indicated in perinatal complications, sepsis, acute/chronic renal disease, labor or neonatal complications, diabetes, and UTI/pyelonephritis. Gentamicin forms the first line of treatment for many disorders in both developing and developed markets. Its usage is particularly high in developing regions where older gentamicin is a cost-effective and efficacious drug for many infectious diseases. Thus, its demand is consistently growing for a range of bacterial infection related diseases, with several players using it in combinations.

North America dominates the global aminoglycoside market

Geographically the aminoglycoside market is classified into North America, South America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global aminoglycoside market in terms of value due to increasing incidence of bacterial infections. The growing demand for early-phase diagnosis and treatment of infectious diseases is expected to drive the growth of the aminoglycoside market in North America. According to the 2017 data published by the Centres for Disease Control & Prevention (CDC), in 2016 the total approximate number of visits in the US, to physician offices for infectious diseases was 16.8 million. The increasing incidence rate and high patient-visit volume for infectious diseases is the primary driver for North America's largest share in Aminoglycoside market

Europe is the second largest market for aminoglycoside in terms of value as there are favorable government policies regarding health care infrastructure and awareness of the population.

Competitive Landscape

The market studied is composed of a large number of players and includes both small and large pharmaceutical manufacturers. Additionally, the increasing antibiotic resistance has prompted many early-stage biotechnology enterprises to enter this market. The expiry of patent exclusivity has led to large scale generic manufacturing of aminoglycosides, particularly in the developing region of Asia-Pacific.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Incurable Status of the Disease
    • 4.2.2 Global increase in Aging Population
    • 4.2.3 Increasing Prevalence of Brain Disorders
  • 4.3 Market Restraints
    • 4.3.1 Adverse and Toxic Reactions Associated with Aminoglycosides
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Product
    • 5.1.1 Neomycin
    • 5.1.2 Tobramycin
    • 5.1.3 Gentamicin
    • 5.1.4 Amikacin
    • 5.1.5 Paromomycin
    • 5.1.6 Streptomycin
    • 5.1.7 Kanamycin
    • 5.1.8 Other Aminoglycosides
  • 5.2 Route of Administration
    • 5.2.1 Parenteral
    • 5.2.2 Intra-mammary
    • 5.2.3 Topical
    • 5.2.4 Oral
  • 5.3 Application
    • 5.3.1 Veterinary
    • 5.3.2 Skin Infection
    • 5.3.3 Respiratory Diseases
    • 5.3.4 UTI & Pelvic Diseases
    • 5.3.5 Other Diseases
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alfasan International BV
    • 6.1.2 Hangzhou Uniwise International Co., Ltd.
    • 6.1.3 HuvePharma
    • 6.1.4 Jiangxi Bolai Pharmacy Co., Ltd.
    • 6.1.5 Kremoint Pharma Pvt. Ltd
    • 6.1.6 Medico Remedies Pvt. Ltd
    • 6.1.7 Medson Pharmaceuticals
    • 6.1.8 Vega Pharma Ltd.
    • 6.1.9 Xian Wison Biological Technology Co., Ltd.
    • 6.1.10 Yi Chang Veterinary Medicine Factory

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top